InnoCan Pharma (TSE:INNO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innocan Pharma has reported impressive financial results for the third quarter of 2024, with a 174% year-over-year increase in 9-month revenues to $24 million, primarily driven by its subsidiary BI Sky Global Ltd. The company has also turned its financial performance around, achieving a net profit of $0.3 million compared to a net loss in the previous year, showcasing strong operational momentum and successful product introductions.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.